 |
市场调查报告书
商品编码
1517636
维生素 D 治疗市场 - 给药途径（口服、肠胃外）、类型（非处方药、处方）、应用（骨质疏鬆症、佝偻病、肌肉无力）、年龄层（儿童、成人、老年人）、配销通路、全球预测（2024 - 2032 年） ）Vitamin D Therapy Market - Route of Administration (Oral, Parenteral), Type (OTC, Prescription), Application (Osteoporosis, Rickets, Muscle Weakness), Age Group (Children, Adults, Geriatric), Distribution Channel, Global Forecast (2024 - 2032) |
||||||
在全球范围内日益增长的采用和需求的推动下，维生素 D 疗法市场规模预计 2024 年至 2032 年间复合年增长率为 11.4%。消费者和医疗保健专业人员越来越认识到维生素 D 在维持整体健康（包括骨骼健康、免疫功能和心血管健康）方面的重要作用。随着越来越多的研究强调补充维生素 D 在预防慢性疾病方面的潜在益处，补充剂和疗法也随之大量引入。例如，2024 年2 月，Cadila Pharmaceuticals 推出了一种用于治疗维生素D 缺乏症的胆钙化醇水剂製剂，与传统的油性製剂相比，该製剂表现出优异的药物动力学(PK)和药效学(PD)。
老年人口的增加，特别是在北美和欧洲等已开发地区，也推动了市场的成长。由于皮肤合成和饮食摄取量减少，老年人也容易缺乏维生素 D，导致补充维生素 D 的需求增加。各年龄层的生活方式的改变，包括室内久坐习惯和有限的阳光照射，将进一步推动产业扩张。
维生素D治疗产业分为给药途径、类型、应用、年龄层、配销通路和地区。
根据类型，由于人们越来越认识到维生素 D 缺乏症是全球重大的公共卫生问题，因此到 2032 年，处方药领域的市场价值将出现显着的复合年增长率。医疗保健提供者越来越多地开出维生素 D 补充剂处方，作为对确诊缺乏维生素 D 或缺乏维生素 D 的高风险患者的治疗干预措施的一部分。处方强度维生素 D 配方可根据患者个别需求进行精确剂量调整，以确保有效管理维生素 D 缺乏相关疾病，例如骨质疏鬆症、低血钙症和某些自体免疫疾病。
由于维生素 D 在改善皮肤健康和免疫功能方面发挥重要作用，皮肤病应用领域的维生素 D 治疗市场预计将在 2024 年至 2032 年期间产生收入。维生素 D 有助于调节免疫反应并促进皮肤细胞生长和修復，使其特别有利于管理各种皮肤状况。患有慢性皮肤病的人通常会因阳光照射有限或皮肤屏障功能受损而导致维生素 D 合成受损，导致他们更加依赖补充剂来维持最佳水平。
到 2032 年，亚太地区维生素 D 治疗产业将录得可观的成长速度。这提高了医疗保健专业人员和消费者对补充维生素 D 重要性的认识。各种维生素 D 产品的供应，包括针对地区饮食偏好和医疗保健需求量身定制的强化食品和补充剂，也推动了市场的成长。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 人们对维生素 D 缺乏症的认识不断增强
- 人口老化加剧
- 非处方药的供应
- 产业陷阱与挑战
- 与治疗相关的副作用
- 成长动力
- 成长潜力分析
- 监管环境
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按管理途径，2021 - 2032 年
- 主要趋势
- 口服
- 注射用
第 6 章：市场估计与预测：按类型，2021 - 2032
- 主要趋势
- 非处方药
- 处方药
第 7 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 骨质疏鬆症
- 肌肉无力
- 疳
- 自体免疫疾病
- 皮肤病
- 其他应用
第 8 章：市场估计与预测：按年龄划分，2021 - 2032
- 主要趋势
- 老年科
- 成年人
- 孩子们
第 9 章：市场估计与预测：按配销通路，2021 - 2032
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第 10 章：市场估计与预测：按地区划分，2021 - 2032 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 11 章：公司简介
- Abbott Laboratories
- Alkem Laboratories Ltd.
- Atrium Innovations
- Biotics Research Corporation
- Cadila Healthcare Ltd.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Ortho Molecular Products
- Pfizer, Inc.
- Sanofi
Vitamin D Therapy Market size is anticipated to register 11.4% CAGR between 2024 and 2032, driven by the increasing adoption and demand worldwide. There is a growing awareness among consumers and healthcare professionals about the essential role of vitamin D in maintaining overall health, including bone health, immune function, and cardiovascular health. As more research highlights the potential benefits of vitamin D supplementation in preventing chronic diseases, there has been significant introduction of supplements and therapies. For instance, in February 2024, Cadila Pharmaceuticals launched an aqueous formulation of cholecalciferol for the treatment of vitamin D deficiency for exhibiting superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to conventional oil-based formulations.
Rising geriatric population, particularly in developed regions like North America and Europe, is also fueling the market growth. Older adults are also susceptible to vitamin D deficiency on account of reduced skin synthesis and dietary intake, leading to an increased need for supplementation. Lifestyle changes, including indoor sedentary habits and limited sun exposure, across various age groups, will further drive the industry expansion.
The vitamin D therapy industry is divided into route of administration, type, application, age group, distribution channel, and region.
Based on type, the market value from the prescription drugs segment will witness notable CAGR through 2032 due to the rising recognition of vitamin D deficiency as a significant public health concern worldwide. Healthcare providers are increasingly prescribing vitamin D supplements as part of therapeutic interventions for patients with diagnosed deficiencies or at high risk of deficiency. Prescription-strength vitamin D formulations allow precise dosing tailored to individual patient needs for ensuring effective management of deficiency-related conditions, such as osteoporosis, hypocalcemia, and certain autoimmune disorders.
Vitamin D therapy market from the skin diseases application segment is slated to generate revenue during 2024-2032 owing to the essential role to improve skin health and immune function. Vitamin D helps in regulating the immune response and promoting skin cell growth and repair, making it particularly beneficial in the management of various skin conditions. Individuals with chronic skin diseases often have impaired vitamin D synthesis due to limited sun exposure or compromised skin barrier function, leading to the increased reliance on supplements to maintain optimal levels.
Asia Pacific vitamin D therapy industry will record decent growth rate through 2032. This is attributed to the increasing prevalence of vitamin D deficiency among the regional population due to factors, such as indoor lifestyles, limited sun exposure, and dietary habits. This has led to heightened awareness among healthcare professionals and consumers about the importance of vitamin D supplementation. The availability of a diverse range of vitamin D products, including fortified foods and supplements, tailored to regional dietary preferences and healthcare needs, is also driving the market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing awareness of vitamin D deficiency
- 3.2.1.2 Increasing ageing population
- 3.2.1.3 Availability of OTC drugs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects associated with therapy
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Oral
- 5.3 Parenteral
Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 OTC drugs
- 6.3 Prescription drugs
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Osteoporosis
- 7.3 Muscle weakness
- 7.4 Rickets
- 7.5 Autoimmune disorders
- 7.6 Skin diseases
- 7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Geriatric
- 8.3 Adults
- 8.4 Children
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Hospital pharmacies
- 9.3 Retail pharmacies
- 9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 Abbott Laboratories
- 11.2 Alkem Laboratories Ltd.
- 11.3 Atrium Innovations
- 11.4 Biotics Research Corporation
- 11.5 Cadila Healthcare Ltd.
- 11.6 GlaxoSmithKline plc
- 11.7 Merck & Co. Inc.
- 11.8 Ortho Molecular Products
- 11.9 Pfizer, Inc.
- 11.10 Sanofi
